FDA Approves Vimseltinib for Symptomatic Tenosynovial Giant Cell Tumour By Ogkologos - April 4, 2025 619 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the MOTION study Source RELATED ARTICLESMORE FROM AUTHOR Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma EMA Recommends Extension of Therapeutic Indications for Retifanlimab MOST POPULAR Developing Biomarkers for Immunotherapy: A Conversation with Drs. Magdalena Thurin and... July 27, 2018 Encouraging Early Results Seen with Novel MEDI1191 in Advanced Tumours March 1, 2021 ESMO Recommendations on Cancer Care Reflected in Un ECOSOC Ministerial Declaration... August 11, 2025 What to Know About Cancer Clinical Trial Matching Programs March 14, 2023 Load more HOT NEWS How We’re Working to Help People With Cancer Across the World 30-Year-Old Mom of 7 With Terminal Breast Cancer Is Gifted Dream... Jaw Problems Linked to Bone-Modifying Drugs Not as Rare as Once... FDA Grants Accelerated Approval to Zongertinib for Non-squamous NSCLC with HER2...
